Premium
Neuroprotective Natural Products for the Treatment of Parkinson's Disease by Targeting the Autophagy–Lysosome Pathway: A Systematic Review
Author(s) -
Wang ZiYing,
Liu JingYi,
Yang ChuanBin,
Malampati Sandeep,
Huang YingYu,
Li MeiXiang,
Li Min,
Song JuXian
Publication year - 2017
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5834
Subject(s) - autophagy , neuroprotection , lysosome , parkinson's disease , dopaminergic , in vivo , pharmacology , medicine , neuroscience , biology , disease , bioinformatics , dopamine , biochemistry , microbiology and biotechnology , pathology , enzyme , apoptosis
The autophagy–lysosome pathway (ALP) is a primary means by which damaged organelles and long‐lived proteins are removed from cells and their components recycled. Impairment of the ALP has been found to be linked to the pathogenesis of Parkinson's disease (PD), a chronic neurodegenerative disorder characterized by the accumulation of protein aggregates and loss of dopaminergic neurons in the midbrain. In recent years, some active compounds derived from plants have been found to regulate the ALP and to exert neuroprotective effects in experimental models of PD, raising the possibility that autophagy enhancement may be an effective therapeutic strategy in PD treatment. In this review, we summarize recent findings of natural products that enhance ALP and thereby protect against PD. Research articles were retrieved from PubMed using relevant keywords in combination. Papers related to the topic were identified, and then the reliability of the experiments was assessed in terms of methodology. The results suggest that targeting the ALP with natural products is a promising strategy for PD treatment. However, risk of bias exists in some studies due to the defective methodology. Rigorous experimental design following the guidelines of autophagy assays, molecular target identification and in vivo efficacy evaluation is critical for the development of ALP enhancers for PD treatment in future studies. Copyright © 2017 John Wiley & Sons, Ltd.